Actelion Ltd - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Actelion Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2014', provides an overview of the Actelion Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actelion Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Actelion Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Actelion Ltd's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Actelion Ltd's pipeline products

Reasons to buy

- Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Actelion Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Actelion Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Actelion Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actelion Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Actelion Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Actelion Ltd Snapshot 7
Actelion Ltd Overview 7
Key Information 7
Key Facts 7
Actelion Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Actelion Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Actelion Ltd - Pipeline Products Glance 15
Actelion Ltd - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Actelion Ltd - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Actelion Ltd - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Actelion Ltd - Drug Profiles 21
macitentan 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
bosentan 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cadazolid 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
selexipag 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ACT-280778 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ponesimod 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ACT-246475 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ACT-281959 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ACT-389949 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ACT-434964 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ACT-462206 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CRTH2 Receptor Antagonist for Asthma and Allergic Disorders 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
lucerastat 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Orexin Receptor Antagonist for Insomnia 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
S1P1 Receptor Agonist for Immunological Disorders 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule For Cardiovascular Disorders 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule for Immunological Disorders 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule for Malaria 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit DNA Ligase for Staphylococcal Infections 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Compound-49c 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Dual Orexin Receptor Antagonist for Insomnia 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule for Cancer 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Actelion Ltd - Pipeline Analysis 48
Actelion Ltd - Pipeline Products by Target 48
Actelion Ltd - Pipeline Products by Route of Administration 50
Actelion Ltd - Pipeline Products by Molecule Type 51
Actelion Ltd - Pipeline Products by Mechanism of Action 52
Actelion Ltd - Recent Pipeline Updates 54
Actelion Ltd - Dormant Projects 61
Actelion Ltd - Discontinued Pipeline Products 62
Discontinued Pipeline Product Profiles 62
almorexant 62
clazosentan 62
palosuran 62
setipiprant 62
Actelion Ltd - Company Statement 63
Actelion Ltd - Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables
Actelion Ltd, Key Information 7
Actelion Ltd, Key Facts 7
Actelion Ltd - Pipeline by Indication, 2014 9
Actelion Ltd - Pipeline by Stage of Development, 2014 11
Actelion Ltd - Monotherapy Products in Pipeline, 2014 12
Actelion Ltd - Partnered Products in Pipeline, 2014 13
Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2014 14
Actelion Ltd - Pre-Registration, 2014 15
Actelion Ltd - Phase III, 2014 16
Actelion Ltd - Phase II, 2014 17
Actelion Ltd - Phase I, 2014 18
Actelion Ltd - Preclinical, 2014 19
Actelion Ltd - Discovery, 2014 20
Actelion Ltd - Pipeline by Target, 2014 49
Actelion Ltd - Pipeline by Route of Administration, 2014 50
Actelion Ltd - Pipeline by Molecule Type, 2014 51
Actelion Ltd - Pipeline Products by Mechanism of Action, 2014 53
Actelion Ltd - Recent Pipeline Updates, 2014 54
Actelion Ltd - Dormant Developmental Projects,2014 61
Actelion Ltd - Discontinued Pipeline Products, 2014 62
Actelion Ltd, Subsidiaries 67